Foundational Pharmacy Strategies’ Christine Johnston on how rebate structures, pending legislation, and a stalled pipeline are reshaping — and threatening — the biosimilar market heading into 2027.
News|Articles|November 1, 2008
Formulary Digital Edition November 2008
Year-end "Focus on": News and updates on the novel pharmacologic agents reviewed over the past 12 months; Focus on prasugrel; Pharmaceutical pipeline database products
Advertisement
Advertisement
Related to this article
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Pope Leo XIV's lung cancer diagnosis puts a spotlight on low U.S. screening rates
2
Chronic hand eczema needs more than topical steroids | Fall Clinical Derm 2026
3
U.S. employer-covered healthcare costs: It’s still the prices
4
Choosing a first biologic for HS, as recommended by Jennifer Hsiao, M.D. | Fall Clinical Derm 2026
5